Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G, Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, Khasraw M, Vauleon E, Muragaki Y, Di Giacomo AM, Butowski N, Roth P, Qian X, Fu AZ, Liu Y, Potter V, Chalamandaris AG, Tatsuoka K, Lim M, Weller M. Omuro A, et al. Among authors: tatsuoka k. Neuro Oncol. 2023 Jan 5;25(1):123-134. doi: 10.1093/neuonc/noac099. Neuro Oncol. 2023. PMID: 35419607 Free PMC article. Clinical Trial.
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwirtes R, Sampson J, Weller M. Reardon DA, et al. Among authors: tatsuoka k. JAMA Oncol. 2020 Jul 1;6(7):1003-1010. doi: 10.1001/jamaoncol.2020.1024. JAMA Oncol. 2020. PMID: 32437507 Free PMC article. Clinical Trial.
Rejoinder to Letter to the Editor "The Hazards of Period Specific and Weighted Hazard Ratios".
Lin RS, Lin J, Roychoudhury S, Anderson KM, Hu T, Huang B, Leon LF, Liao JJZ, Liu R, Luo X, Mukhopadhyay P, Qin R, Tatsuoka K, Wang X, Wang Y, Zhu J, Chen TT, Iacona R; Cross-Pharma Non-Proportional Hazards Working Group. Lin RS, et al. Among authors: tatsuoka k. Stat Biopharm Res. 2020 Oct 28;12(4):520-521. doi: 10.1080/19466315.2020.1825522. Stat Biopharm Res. 2020. PMID: 34191985 Free PMC article. No abstract available.
Potential candidate genomic biomarkers of drug induced vascular injury in the rat.
Dalmas DA, Scicchitano MS, Mullins D, Hughes-Earle A, Tatsuoka K, Magid-Slav M, Frazier KS, Thomas HC. Dalmas DA, et al. Among authors: tatsuoka k. Toxicol Appl Pharmacol. 2011 Dec 1;257(2):284-300. doi: 10.1016/j.taap.2011.09.015. Epub 2011 Sep 24. Toxicol Appl Pharmacol. 2011. PMID: 21983523
Oral L-histidine exerts antihypertensive effects via central histamine H3 receptors and decreases nitric oxide content in the rostral ventrolateral medulla in spontaneously hypertensive rats.
Toba H, Nakamori A, Tanaka Y, Yukiya R, Tatsuoka K, Narutaki M, Tokitaka M, Hariu H, Kobara M, Nakata T. Toba H, et al. Among authors: tatsuoka k. Clin Exp Pharmacol Physiol. 2010 Jan;37(1):62-8. doi: 10.1111/j.1440-1681.2009.05227.x. Clin Exp Pharmacol Physiol. 2010. PMID: 19566844
Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat.
Fielden MR, Nie A, McMillian M, Elangbam CS, Trela BA, Yang Y, Dunn RT 2nd, Dragan Y, Fransson-Stehen R, Bogdanffy M, Adams SP, Foster WR, Chen SJ, Rossi P, Kasper P, Jacobson-Kram D, Tatsuoka KS, Wier PJ, Gollub J, Halbert DN, Roter A, Young JK, Sina JF, Marlowe J, Martus HJ, Aubrecht J, Olaharski AJ, Roome N, Nioi P, Pardo I, Snyder R, Perry R, Lord P, Mattes W, Car BD; Predictive Safety Testing Consortium; Carcinogenicity Working Group. Fielden MR, et al. Among authors: tatsuoka ks. Toxicol Sci. 2008 May;103(1):28-34. doi: 10.1093/toxsci/kfn022. Epub 2008 Feb 14. Toxicol Sci. 2008. PMID: 18281259
12 results